Lineage Cell Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
6analysts covering
FY Revenue (est.)
$17.9Mnext fiscal year
FY EPS (est.)
-$0.07next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, cash equivalents, and marketable securities Quarterly53.4MTarget: Sufficient to fund operations into Q2 2028
Quarterly Collaboration and Licensing Revenue Quarterly1.7MTarget: Variable based on Roche/Genentech milestone achievements
Net Loss Attributable to Shareholders Quarterly-4.8MTarget: Narrowing losses as pipeline programs mature
Watch Items
- OpRegen (RG6501) Clinical Progress and MilestonesTrigger: Achievement of development milestones under the Roche/Genentech collaborationAction: Monitor partner updates and potential milestone payments of up to $615 million remaining.
- OPC1 Phase 1/2a Clinical Trial Data and EnrollmentTrigger: Release of updated clinical data or regulatory feedback on OPC1 for spinal cord injuryAction: Evaluate clinical efficacy signals and safety profiles to assess progression toward registrational trials.
- ReSonance (ANP1) Go/No-Go DecisionTrigger: Preclinical evaluation completion in the second half of 2026Action: Assess whether to advance the auditory neuron progenitor program into clinical development.
Research as of 19 Jun 2026